Want to see ES:ORY full AI Analyst Report?
Top Page
Oryzon Genomics SA
(BME:ORY)
Select Model
Select Model
Rating:46Neutral
Price Target:
€3.00
▼(-6.83% Downside)
Action:Reiterated
Date:03/06/26
The score is held back primarily by ongoing losses, inconsistent revenue, and persistent cash burn despite a comparatively supportive balance sheet with low leverage. Technically, the stock is in a downtrend (below key moving averages) with weak momentum, though indicators appear oversold. Valuation is difficult to assess with a negative P/E and no dividend data.
Positive Factors
Low Leverage / Supportive Balance Sheet
Oryzon's low debt-to-equity and meaningful equity base provide financing flexibility for multi-year clinical development, reducing near-term refinancing risk and preserving optionality for partnerships or licensing deals that require runway to reach value-driving catalysts.
Negative Factors
Persistent Operating Losses
Sustained operating and net losses indicate the company remains pre-commercial and reliant on external financing; prolonged unprofitability can dilute shareholders, constrain strategic choices, and necessitate recurring capital raises that distract management from long-term value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Supportive Balance Sheet
Oryzon's low debt-to-equity and meaningful equity base provide financing flexibility for multi-year clinical development, reducing near-term refinancing risk and preserving optionality for partnerships or licensing deals that require runway to reach value-driving catalysts.
Read all positive factors
Oryzon Genomics SA (ORY) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€243.81M
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue GrowthN/A
EPS Growth58.10%
CountryES
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding79,887,700
10 Day Avg. Volume2,474,153
30 Day Avg. Volume1,678,358
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.48Price Target Upside101.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)€8.20M
Oryzon Genomics SA Business Overview & Revenue Model
Company Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinica...
How the Company Makes Money
Oryzon Genomics primarily aims to generate revenue through the development and commercialization of its drug candidates and through partnering activities typical of clinical-stage biotech companies. Potential revenue streams include: (1) collabora...
Oryzon Genomics SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.58M | 0.00 | 7.36M | 14.19M | 0.00 | 10.62M |
| Gross Profit | 11.06M | -133.91K | 7.06M | 13.95M | 15.23M | 9.87M |
| EBITDA | -1.69M | -6.29M | -4.43M | -4.43M | -5.35M | -6.88M |
| Net Income | -4.04M | -2.61M | -3.67M | -3.35M | -4.23M | -4.69M |
Balance Sheet | ||||||
| Total Assets | 138.35M | 144.52M | 108.72M | 106.90M | 103.70M | 95.38M |
| Cash, Cash Equivalents and Short-Term Investments | 31.11M | 28.37M | 5.62M | 12.26M | 21.32M | 28.72M |
| Total Debt | 13.73M | 11.94M | 16.21M | 13.69M | 17.44M | 17.66M |
| Total Liabilities | 24.13M | 26.68M | 21.67M | 25.13M | 31.13M | 24.12M |
| Stockholders Equity | 114.22M | 105.45M | 87.04M | 81.77M | 72.57M | 71.26M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.42M | -13.40M | -15.08M | -16.12M | -15.39M |
| Operating Cash Flow | 0.00 | -2.36M | -5.69M | -574.96K | -1.85M | -3.63M |
| Investing Cash Flow | 0.00 | -11.04M | -7.81M | -14.50M | -14.27M | -11.72M |
| Financing Cash Flow | 0.00 | 36.13M | 6.87M | 6.02M | 8.71M | 4.12M |
Oryzon Genomics SA Technical Analysis
Neutral
3.22
Price Trends
2.98
Positive
2.95
Positive
3.08
Positive
Market Momentum
0.04
Positive
50.82
Neutral
46.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ORY, the sentiment is Neutral. The current price of 3.22 is above the 20-day moving average (MA) of 3.11, above the 50-day MA of 2.98, and above the 200-day MA of 3.08, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.82 is Neutral, neither overbought nor oversold. The STOCH value of 46.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:ORY.
Oryzon Genomics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €1.34B | 16.23 | 35.74% | 1.04% | 28.27% | 307.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €1.43B | 10.77 | 18.13% | 3.51% | 23.66% | -28.51% | |
46 Neutral | €243.81M | -111.22 | -2.58% | ― | ― | 58.10% | |
46 Neutral | €219.70M | 49.81 | 2.03% | 1.91% | -3.23% | -60.06% |
* Healthcare Sector Average
ES:ORY
Oryzon Genomics SA
2.83
0.13
4.70%
ES:FAE
Faes Farma
4.55
0.16
3.74%
ES:RJF
LABORATORIO REIG JOFRE
2.70
-0.25
-8.35%
ES:PHM
Pharma Mar SA
75.85
-4.45
-5.54%
ES:IKM
1nKemia IUCT Group SA
0.31
0.00
0.00%
Oryzon Genomics SA Corporate Events
Oryzon Genomics launches capital raise and secures €25m anchor commitment for R&D
Jul 1, 2026
Oryzon Genomics has approved a cash capital increase of up to €10 million, potentially rising to €15 million, via an accelerated private placement of new shares aimed at strengthening its balance sheet and speeding up its acute myeloid...
Oryzon Updates Loyalty Share Double Voting Rights and Total Votes
Jun 9, 2026
Oryzon Genomics has updated its share capital structure after the removal of 102,530 shares that carried double voting rights for shareholder loyalty. Following this adjustment, the company now reports 8,864,432 shares with double voting rights an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.